Product Description
Sun Pharma was developing sparc-147609, an intravenous agent for Ovarian Carcinoma. (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT00862355)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sun Pharma
Company Location:
Company Founding Year: 1983
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Ovarian Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00862355 |
DOX_2I_1476_09 | P1 |
Completed |
Ovarian Cancer |
2010-12-01 |
2019-03-18 |
Recent News Events
Date |
Type |
Title |
|---|